Atara Biotherapeutics Inc. (NASDAQ:ATRA) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a note issued to investors on Friday.

According to Zacks, “Atara Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company. It is focused on developing therapeutics for serious unmet medical needs, with an initial focus on muscle wasting conditions and oncology. The company’s lead programs are focused on myostatin and activin, members of the TGF-beta family of proteins that have demonstrated the potential to have therapeutic benefit in a number of clinical indications. Its lead product candidate is PINTA 745, which is in a Phase II clinical trial for the treatment of protein-energy wasting in end-stage renal disease patients. Atara Biotherapeutics, Inc. is headquartered in Brisbane, California. “

Several other equities research analysts have also recently weighed in on ATRA. JMP Securities reiterated a “buy” rating on shares of Atara Biotherapeutics in a research report on Saturday, July 9th. Canaccord Genuity reissued a “buy” rating on shares of Atara Biotherapeutics in a research note on Tuesday, June 7th. Jefferies Group reissued a “buy” rating and set a $25.00 target price on shares of Atara Biotherapeutics in a research note on Tuesday, August 9th. Goldman Sachs Group Inc. lowered shares of Atara Biotherapeutics from a “neutral” rating to a “sell” rating and cut their target price for the stock from $23.00 to $16.00 in a research note on Thursday, September 15th. Finally, Citigroup Inc. increased their target price on shares of Atara Biotherapeutics from $8.00 to $10.00 and gave the stock a “sell” rating in a research note on Friday, August 19th. Two equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the company’s stock. Atara Biotherapeutics presently has a consensus rating of “Hold” and an average target price of $26.14.

Atara Biotherapeutics (NASDAQ:ATRA) opened at 19.17 on Friday. Atara Biotherapeutics has a 12 month low of $13.31 and a 12 month high of $45.91. The company’s market capitalization is $552.31 million. The stock’s 50 day moving average is $21.49 and its 200-day moving average is $19.99.

Atara Biotherapeutics (NASDAQ:ATRA) last posted its quarterly earnings data on Monday, August 8th. The company reported ($0.66) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.61) by $0.05. On average, analysts expect that Atara Biotherapeutics will post ($2.85) EPS for the current year.

In other Atara Biotherapeutics news, CEO Isaac E. Ciechanover sold 9,600 shares of the firm’s stock in a transaction on Friday, July 8th. The shares were sold at an average price of $22.88, for a total value of $219,648.00. Following the transaction, the chief executive officer now directly owns 223,228 shares of the company’s stock, valued at $5,107,456.64. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Christopher Haqq sold 1,346 shares of the firm’s stock in a transaction on Monday, August 15th. The shares were sold at an average price of $22.32, for a total transaction of $30,042.72. Following the completion of the transaction, the insider now directly owns 295,294 shares in the company, valued at $6,590,962.08. The disclosure for this sale can be found here. 16.10% of the stock is currently owned by company insiders.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. BlackRock Group LTD raised its position in Atara Biotherapeutics by 76.8% in the first quarter. BlackRock Group LTD now owns 5,400 shares of the company’s stock worth $103,000 after buying an additional 2,345 shares during the period. Barclays PLC increased its stake in shares of Atara Biotherapeutics by 2,266.0% in the second quarter. Barclays PLC now owns 4,803 shares of the company’s stock valued at $108,000 after buying an additional 4,600 shares in the last quarter. BlackRock Inc. increased its stake in shares of Atara Biotherapeutics by 464.3% in the second quarter. BlackRock Inc. now owns 6,100 shares of the company’s stock valued at $137,000 after buying an additional 5,019 shares in the last quarter. PNC Financial Services Group Inc. increased its stake in shares of Atara Biotherapeutics by 6,736.5% in the second quarter. PNC Financial Services Group Inc. now owns 6,563 shares of the company’s stock valued at $148,000 after buying an additional 6,467 shares in the last quarter. Finally, BlackRock Advisors LLC increased its stake in shares of Atara Biotherapeutics by 30.2% in the second quarter. BlackRock Advisors LLC now owns 10,186 shares of the company’s stock valued at $229,000 after buying an additional 2,361 shares in the last quarter. 75.50% of the stock is currently owned by hedge funds and other institutional investors.

Atara Biotherapeutics Company Profile

Atara Biotherapeutics, Inc is a clinical-stage biopharmaceutical company. Its segment is the business of developing and commercializing therapeutics. It has approximately two groups of product candidates, such as allogeneic or third-party derived antigen-specific T-cells, and molecularly targeted biologics.

5 Day Chart for NASDAQ:ATRA

Get a free copy of the Zacks research report on Atara Biotherapeutics (ATRA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Atara Biotherapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.